Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Bangladesh | Egypt | Greece | India | Ireland | Pakistan | Philippines | Saudi Arabia | South Africa | Taiwan | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: University of Queensland
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Inflammatory Bowel Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| Nil | P3 |
Completed |
Inflammatory Bowel Diseases |
2014-02-20 |
2024-08-29 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/09/2024 |
PubMed |
A case report of refractory amebic colitis and literature review. |
|
01/01/2024 |
PubMed |
Chitosan-based intelligent polymeric networks for site-specific colon medication delivery: A comprehensive study on controlled release of diloxanide furoate and network formation dynamics. |
|
01/01/2024 |
PubMed |
Amebiasis. |